Literature DB >> 22020800

Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures.

Han-Seong Kim1, Yong-Bock Choi, Jung-Hwa Lee, Seong-Yeol Park, Hyun-Kyoung Kim, Jae-Soo Koh, Sang-Yeop Yi, Kyung-Tae Kim, Kyung-Uk Hong, Joobae Park, Chang-Dae Bae, Kyeong-Man Hong.   

Abstract

PURPOSE: Proliferation activity has long been known to be one of the strongest prognostic factors in many different cancers. Nevertheless, microscopic evaluation of mitotic figures remains time-consuming and, furthermore, is relatively subjective. As the expression of cytoskeleton-associated protein 2 (CKAP2) is closely related to the mitotic phase, CKAP2 was evaluated as a surrogate mitotic figure (MF) marker.
METHODS: A monoclonal antibody specific to human CKAP2 was produced, and immunohistochemistry was performed on normal tissue array sections and 30 breast cancer tissues.
RESULTS: The expression of CKAP2 in the normal human tissues was limited to well-known cell proliferation zones. Strong, readily visible, condensed chromatin staining of CKAP2 was observed specifically in mitotic cells, and the number of these cells was tightly correlated with the MF count in breast cancer tissues (P < 0.001, ρ = 0.743), suggesting its usefulness as a surrogate marker for MF counting.
CONCLUSION: Immunohistochemical staining with CKAP2 monoclonal antibody can be considered to be a new, effective approach to the assessment of proliferation activity in cancer tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020800     DOI: 10.1007/s00432-011-1053-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project.

Authors:  P J van Diest; J P Baak; P Matze-Cok; E C Wisse-Brekelmans; C M van Galen; P H Kurver; S M Bellot; J Fijnheer; L H van Gorp; W S Kwee
Journal:  Hum Pathol       Date:  1992-06       Impact factor: 3.466

2.  Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas.

Authors:  L Maouche-Chrétien; N Deleu; C Badoual; P Fraissignes; R Berger; P Gaulard; P H Roméo; K Leroy-Viard
Journal:  Oncogene       Date:  1998-09-10       Impact factor: 9.867

3.  Targeting aurora kinases as therapy in multiple myeloma.

Authors:  Yijiang Shi; Tony Reiman; Weiqun Li; Christopher A Maxwell; Subrata Sen; Linda Pilarski; Tracy R Daniels; Manuel L Penichet; Rick Feldman; Alan Lichtenstein
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

4.  Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.

Authors:  Phyllis A Gimotty; Patricia Van Belle; David E Elder; Todd Murry; Kathleen T Montone; Xiaowei Xu; Susan Hotz; Shane Raines; Michael E Ming; Peter Wahl; Dupont Guerry
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

5.  Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study.

Authors:  D Amadori; O Nanni; M Marangolo; P Pacini; A Ravaioli; A Rossi; A Gambi; G Catalano; D Perroni; E Scarpi; D C Giunchi; A Tienghi; A Becciolini; A Volpi
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

6.  Functional importance of the anaphase-promoting complex-Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis.

Authors:  Kyung Uk Hong; Young Soo Park; Yeon-Sun Seong; Dongmin Kang; Chang-Dae Bae; Joobae Park
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

Review 7.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.

Authors:  Jan P A Baak; Einar Gudlaugsson; Ivar Skaland; Lydia Hui Ru Guo; Jan Klos; Tone Hoel Lende; Håvard Søiland; Emiel A M Janssen; Axel Zur Hausen
Journal:  Breast Cancer Res Treat       Date:  2008-07-30       Impact factor: 4.872

Review 8.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

9.  Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis.

Authors:  Kyung Uk Hong; Hyun-Jun Kim; Hyo-Sil Kim; Yeon-Sun Seong; Kyeong-Man Hong; Chang-Dae Bae; Joobae Park
Journal:  J Biol Chem       Date:  2009-04-15       Impact factor: 5.157

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  6 in total

1.  Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2.

Authors:  He Nan Ma; Hai Jun Chen; Ji Quan Liu; Wen Tao Li
Journal:  Cell Death Dis       Date:  2022-07-19       Impact factor: 9.685

2.  CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.

Authors:  Sung Hoon Sim; Chang-Dae Bae; Youngmi Kwon; Hai-Li Hwang; Shiv Poojan; Hye-In Hong; Kyungtae Kim; Seo-Hee Kang; Han-Seong Kim; Tae-Hyun Um; In Hae Park; Keun Seok Lee; So-Youn Jung; Seeyoun Lee; Han-Sung Kang; Eun Sook Lee; Mi-Kyung Kim; Kyeong-Man Hong; Jungsil Ro
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

3.  Behavior of dicentric chromosomes in budding yeast.

Authors:  Diana Cook; Sarah Long; John Stanton; Patrick Cusick; Colleen Lawrimore; Elaine Yeh; Sarah Grant; Kerry Bloom
Journal:  PLoS Genet       Date:  2021-03-18       Impact factor: 5.917

4.  Knockdown of CKAP2 Inhibits Proliferation, Migration, and Aggregate Formation in Aggressive Breast Cancer.

Authors:  Alexsandro Dos Santos; Geneviève Ouellete; Caroline Diorio; Sabine Elowe; Francine Durocher
Journal:  Cancers (Basel)       Date:  2022-08-02       Impact factor: 6.575

5.  Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer.

Authors:  Han-Seong Kim; Jae-Soo Koh; Yong-Bock Choi; Jungsil Ro; Hyun-Kyoung Kim; Mi-Kyung Kim; Byung-Ho Nam; Kyung-Tae Kim; Vishal Chandra; Hye-Sil Seol; Woo-Chul Noh; Eun-Kyu Kim; Joobae Park; Chang-Dae Bae; Kyeong-Man Hong
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

6.  Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients.

Authors:  Young-Woo Kim; Bang Wool Eom; Myeong-Cherl Kook; Han-Seong Kim; Mi-Kyung Kim; Hai-Li Hwang; Vishal Chandra; Shiv Poojan; Yura Song; Jae-Soo Koh; Chang-Dae Bae; Jungsil Ro; Kyeong-Man Hong
Journal:  Exp Mol Med       Date:  2015-11-06       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.